EventsUpcoming EventsMark your calendars for: 2nd Annual Kure It Networking Cruise and Poker RunThursday, July 22, 2010 at 7pm at the Balboa Bay Club Join us immediately following the CSSA Owners Summit for a one-hour electric boat cruise on the beautiful waters of the Newport Bay. There will be friendly competition, appetizers, drinks, and networking opportunities- all while raising money for cancer research. For more information or to register, download the registration form or contact Kure It at 949-428-7081 or kellien@kureit.org. See pictures from last years event.
2009 Cruise 2nd Annual 901 Club ReunionSaturday, August 21, 2010 Join fellow Trojans and friends for a night of fun at the Newport Sports Museum. For more information contact Kure It at 949-428-7081 or kellien@kureit.org. |
About the Kure It! Kidney Cancer Research FundThe Kure It! Kidney Cancer Research Fund is a not-for-profit affiliate fund of the City of Hope National Medical Center. Established in the spring of 2007, the Kure It! Kidney Cancer Research Fund is dedicated entirely to funding kidney cancer research under the direction of Dr. Robert Figlin, Associate Director for Clinical Oncology at the City of Hope in Los Angeles. All donations made to the KIKCRF are tax-deductible under Section 501(c)(3) of the Internal Revenue Code. Incidence and Mortality Rates of Kidney, Breast, Prostate CancersWhen compared to breast and prostate cancer, kidney cancer has the highest mortality rate, despite having the lowest projected incidence. In the U.S. alone, roughly 25% of kidney cancer patients will lose their battle this year as compared to 23% of breast cancer patients and 12% of prostate cancer patients. Mortality Ratios for Prostate, Breast, Melanoma & Kidney Cancers
And yet, kidney cancer receives approximately 1/17 of the amount of funding as breast cancer and only 1/10 the amount as prostate cancer. Federal Funding for Prostate, Breast, Melanoma & Kidney Cancers
Interesting Fact:While melanoma has a slightly higher incidence rate than kidney cancer (59,940 v. 51,190) and lower mortality rate (14% v. 25%), the National Cancer Institute provides over three times as much funding for melanoma research than it does for kidney cancer research ($97,199,000 v. $31,055,000). (Sources: Incidence and Mortality estimates for 2007 developed by the American Cancer Society based on incidence data from the NCI's Surveillance, Epidemiology, and End Results Program and on death data from the National Center for Health Statistics, Centers for Disease Control and Prevention. Funding figures based on the Fiscal Year 2006 as reported by the Financial Management Branch of the National Cancer Institute.) |